Early-stage opportunity Clinical-stage biotech firm with revenue between one and ten million and ongoing funding activities. Potential sales focus on CRO services, contract research, and research partnerships to accelerate development and de-risk funding goals.
Funding alignment Recent and ongoing participation in innovation and financing events (Life Science Innovation Northwest) plus a CRADA with NIH suggests interest in grant support, collaboration agreements, and milestone-based funding models for shared research programs.
Strategic partnerships Past NIH CRADA and presentation at industry events indicate receptiveness to collaboration, technology licensing, and co-development opportunities across biotech tooling, data management, and translational research services.
Operational focus Small team size implies high reliance on external vendors and specialized service providers. Upsell opportunities include scalable clinical trial support, regulatory affairs consulting, and cloud-based data infrastructure partnerships.
Tech and data potential Tech stack shows reliance on cloud, web, and data tools; opportunities exist to offer AI/ML data analysis, cloud optimization, cybersecurity, or platform integrations to enhance research efficiency and data sharing with sponsors.